The restoration of kidney mitochondria function by inhibition of angiotensin-II production in rats with acute adriamycin-induced nephrotoxicity

Renal Failure

Volumn 36, Issue 4, 2014, Pages 606-612

  Taskin, Eylem ^a   Ozdogan, Kalender ^b   Kunduz Kindap, Elvan ^b   Dursun, Nurcan ^b  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

Adriamycin induced nephrotoxicity; Aliskren; Captopril; Mitochondrial ATP; Mitochondrial membrane potential; Oxidative stress index

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALISKIREN; ANGIOTENSIN II; CAPTOPRIL; CREATINE KINASE; DOXORUBICIN; REACTIVE OXYGEN METABOLITE; AMIDE; FUMARIC ACID DERIVATIVE; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CYTOSOL; DRUG MECHANISM; ENZYME INHIBITION; HOMOGENATE; KIDNEY FUNCTION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN ANGIOTENSIN DISORDER; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TOXICITY;

ADENOSINE TRIPHOSPHATE; AMIDES; ANGIOTENSIN II; ANIMALS; CAPTOPRIL; CREATINE KINASE; DOXORUBICIN; FUMARATES; KIDNEY; KIDNEY DISEASES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84899023867     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.882737     Document Type: Article

References (43)

1. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23(1):15-25
2. Malarkodi KP, Balachandar AV, Varalakshmi P. Protective effect of lipoic acid on Adriamycin induced lipid peroxidation in rat kidney. Mol Cell Biochem. 2003;247(1-2):9-13
3. Malarkodi KP, Balachandar AV, Varlakshmi P. The influence of lipoic acid on Adriamycin-induced hyperlipidemic nephrotoxicity in rats. Mol Cell Biochem. 2003;247(1-2):139-145
4. Ajith TA, Aswathy MS, Hema U. Protective effect of Zingiber officinale roscoe against anticancer drug doxorubicin-induced acute nephrotoxicity. Food Chem Toxicol. 2008;46(9):3178-3181
5. Dursun N, Taskin E, Ozturk F. Protection against Adriamycininduced cardiomyopathy by carnosine in rats: role of endogenous antioxidants. Biol Trace Elem Res. 2011;143(1):412-424
6. Dursun N, Taskin E, Yerer Aycan MB, Sahin L. Selenium-mediated cardioprotection against Adriamycin-induced mitochondrial damage. Drug Chem Toxicol. 2011;34(2):199-207
7. Hou XW, Jiang Y, Wang LF, et al. Protective role of granulocyte colony-stimulating factor against Adriamycin induced cardiac, renal and hepatic toxicities. Toxicol Lett. 2009;187(1):40-44
8. Ozdogan K, Taskin E, Dursun N. Protective effect of carnosine on Adriamycin-induced oxidative heart damage in rats. AKD Anatolian J Cardiol. 2011;11(1):3-10
9. Taskin E, Dursun N. The protection of selenium on Adriamycininduced mitochondrial damage in rat. Biol Trace Elem Res. 2012; 147(1-3):165-171
10. Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE. Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol. 2012;8(4):647-670
11. Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys. 1999;368(2):421-428
12. Chandran K, Aggarwal D, Migrino RQ, et al. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J. 2009;96(4):1388-1398
13. Wallace KB, Starkov AA. Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol. 2000;40:353-388
14. Morin D, Barthelemy S, Zini R, Labidalle S, Tillement JP. Curcumin induces the mitochondrial permeability transition pore mediated by membrane protein thiol oxidation. FEBS Lett. 2001; 495(1-2):131-136
15. Mimnaugh EG, Trush MA, Bhatnagar M, Gram TE. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug Adriamycin. Biochem Pharmacol. 1985;34(6):847-856
16. Ji LL, Mitchell EW. Effects of Adriamycin on heart mitochondrial function in rested and exercised rats. Biochem Pharmacol. 1994; 47(5):877-885
17. Ji Z, Huang C, Liang C, Chen B, Chen S, Sun W. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis. Cell Mol Immunol. 2005; 2(2):150-154
18. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin- induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 2009;60(5):373-381
19. Rashikh A, Pillai KK, Ahmad SJ, Akhtar M, Najmi AK. Aliskiren alleviates doxorubicin-induced nephrotoxicity by inhibiting oxidative stress and podocyte injury. J Renin Angiotensin Aldosterone Syst. 2013;14(1):14-22
20. Han P, Sun H, Xu Y, et al. Lisinopril protects against the adriamycin nephropathy and reverses the renalase reduction: potential role of renalase in adriamycin nephropathy. Kidney Blood Press Res. 2013;37(4-5):295-304
21. Arozal W, Watanabe K, Veeraveedu PT, et al. Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats. J Pharm Pharmacol. 2010;62(12):1776-1783
22. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005; 104(11):2492-2498
23. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157-170
24. de Cavanagh EM, Inserra F, Ferder M, Ferder L. From mitochondria to disease: role of the renin-angiotensin system. Am J Nephrol. 2007;27(6):545-553
25. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012; 52(6):1213-1225
26. Okasora T, Takikawa T, Utsunomiya Y, et al. Suppressive effect of superoxide dismutase on Adriamycin nephropathy. Nephron. 1992; 60(2):199-203
27. Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G. Tubulointerstitial lesions mediate renal damage in Adriamycin glomerulopathy. Kidney Int. 1986;30(4):488-496
28. Mimnaugh EG, Trush MA, Gram TE. A possible role for membrane lipid peroxidation in anthracycline nephrotoxicity. Biochem Pharmacol. 1986;35(23):4327-4335
29. Mansour MA, El-Kashef HA, Al-Shabanah OA. Effect of captopril on doxorubicin-induced nephrotoxicity in normal rats. Pharmacol Res. 1999;39(3):233-237
30. Rashikh A, Abul Kalam N, Akhtar M, Mahmood D, Pillai KK, Ahmad SJ. Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats. Human Exp Toxicol. 2011; 30(2):102-109
31. Boucek Jr. RJ, Steele A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin- induced cardiotoxicity. Cardiovasc Toxicol. 2003; 3(4):319-329
32. Giri SN, Al-Bayati MA, Du X, Schelegle E, Mohr FC, Margolin SB. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother Pharmacol. 2004; 53(2):141-150
33. Yamanaka N, Kato T, Nishida K, Fujikawa T, Fukushima M, Ota K. Elevation of serum lipid peroxide level associated with doxorubicin toxicity and its amelioration by [dl]-alpha-tocopheryl acetate or coenzyme Q10 in mouse (doxorubicin, toxicity, lipid peroxide, tocopherol, coenzyme Q10). Cancer Chemother Pharmacol. 1979; 3(4):223-227
34. Wang YM, Madanat FF, Kimball JC, et al. Effect of vitamin E against Adriamycin-induced toxicity in rabbits. Cancer Res. 1980; 40(4):1022-1027
35. Pandir D, Kara O. Cisplatin-induced kidney damage and the protective effect of bilberry (Vaccinium myrtillus L.): an experimental study. Turkish J Med Sci. 2013;43(6):951-956
36. Munoz M, Rincon J, Pedreanez A, Viera N, Hernandez-Fonseca JP, Mosquera J. Proinflammatory role of angiotensin II in a rat nephrosis model induced by Adriamycin. J Renin Angiotensin Aldosterone Syst. 2011;12(4):404-412
37. Ulu N, Buikema H, van Gilst WH, Navis G. Vascular dysfunction in Adriamycin nephrosis: different effects of Adriamycin exposure and nephrosis. Nephrol Dial Transplant. 2008;23(6):1854-1860
38. Hiona A, Lee AS, Nagendran J, et al. Pretreatment with angiotensin- converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011;142(2):396-403 e393
39. Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy. 2005;25(9):1213-1229
40. Westermann D, Riad A, Lettau O, et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008; 52(6):1068-1075
41. Rashikh A, Pillai KK, Najmi AK. Protective effect of a direct renin inhibitor in acute murine model of cardiotoxcity and nephrotoxicity. Fundam Clin Pharmacol. 2013. [Epub ahead of print]. doi: 10.1111/fcp.12054
42. St-Jacques R, Toulmond S, Auger A, et al. Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors. JRAAS. 2011;12(3):133-145
43. Muller DN, Derer W, Dechend R. Aliskiren - mode of action and preclinical data. J Mol Med (Berl). 2008;86(6):659-662.